• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤免疫微环境的无创成像与胃癌免疫治疗的反应相关。

Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer.

机构信息

Department of General Surgery, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China.

Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China.

出版信息

Nat Commun. 2022 Aug 30;13(1):5095. doi: 10.1038/s41467-022-32816-w.

DOI:10.1038/s41467-022-32816-w
PMID:36042205
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9427761/
Abstract

The tumor immune microenvironment (TIME) is associated with tumor prognosis and immunotherapy response. Here we develop and validate a CT-based radiomics score (RS) using 2272 gastric cancer (GC) patients to investigate the relationship between the radiomics imaging biomarker and the neutrophil-to-lymphocyte ratio (NLR) in the TIME, including its correlation with prognosis and immunotherapy response in advanced GC. The RS achieves an AUC of 0.795-0.861 in predicting the NLR in the TIME. Notably, the radiomics imaging biomarker is indistinguishable from the IHC-derived NLR status in predicting DFS and OS in each cohort (HR range: 1.694-3.394, P < 0.001). We find the objective responses of a cohort of anti-PD-1 immunotherapy patients is significantly higher in the low-RS group (60.9% and 42.9%) than in the high-RS group (8.1% and 14.3%). The radiomics imaging biomarker is a noninvasive method to evaluate TIME, and may correlate with prognosis and anti PD-1 immunotherapy response in GC patients.

摘要

肿瘤免疫微环境(TIME)与肿瘤预后和免疫治疗反应相关。在这里,我们使用 2272 名胃癌(GC)患者开发和验证了一种基于 CT 的放射组学评分(RS),以研究放射组学成像生物标志物与 TIME 中的中性粒细胞与淋巴细胞比值(NLR)之间的关系,包括其与晚期 GC 预后和免疫治疗反应的相关性。该 RS 在预测 TIME 中的 NLR 方面的 AUC 为 0.795-0.861。值得注意的是,在每个队列中,放射组学成像生物标志物在预测DFS 和 OS 方面与 IHC 衍生的 NLR 状态无法区分(HR 范围:1.694-3.394,P<0.001)。我们发现,在接受抗 PD-1 免疫治疗的患者队列中,低 RS 组(60.9%和 42.9%)的客观缓解率明显高于高 RS 组(8.1%和 14.3%)。放射组学成像生物标志物是一种评估 TIME 的非侵入性方法,可能与 GC 患者的预后和抗 PD-1 免疫治疗反应相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/97e72860192e/41467_2022_32816_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/fb9c9b2eba7b/41467_2022_32816_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/6a1b7eaa4cf8/41467_2022_32816_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/fa84a8bfbde8/41467_2022_32816_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/fcc005a6bb35/41467_2022_32816_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/97e72860192e/41467_2022_32816_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/fb9c9b2eba7b/41467_2022_32816_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/6a1b7eaa4cf8/41467_2022_32816_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/fa84a8bfbde8/41467_2022_32816_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/fcc005a6bb35/41467_2022_32816_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/902c/9427761/97e72860192e/41467_2022_32816_Fig5_HTML.jpg

相似文献

1
Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer.肿瘤免疫微环境的无创成像与胃癌免疫治疗的反应相关。
Nat Commun. 2022 Aug 30;13(1):5095. doi: 10.1038/s41467-022-32816-w.
2
Comprehensive assessment of immune context and immunotherapy response via noninvasive imaging in gastric cancer.通过无创成像技术对胃癌的免疫微环境和免疫治疗反应进行全面评估。
J Clin Invest. 2024 Jan 25;134(6):e175834. doi: 10.1172/JCI175834.
3
Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study.非侵入性 CT 成像生物标志物预测胃癌免疫治疗反应:一项多中心研究。
J Immunother Cancer. 2023 Nov 21;11(11):e007807. doi: 10.1136/jitc-2023-007807.
4
Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.中性粒细胞与淋巴细胞比值(NLR)、程序性死亡受体配体1(PD-L1)表达及肿瘤免疫微环境对喉癌的预后影响
Ann Diagn Pathol. 2021 Feb;50:151657. doi: 10.1016/j.anndiagpath.2020.151657. Epub 2020 Nov 5.
5
A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: a multi-cohort study.从 CT 成像中提取的放射组学特征可预测胃癌的 MSI 状态和免疫治疗结果:一项多队列研究。
BMC Cancer. 2024 Apr 1;24(1):404. doi: 10.1186/s12885-024-12174-0.
6
Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.基于机器学习的放射组学特征用于评估乳腺癌 TME 表型和预测抗 PD-1/PD-L1 免疫治疗反应的建立。
Breast Cancer Res. 2024 Jan 29;26(1):18. doi: 10.1186/s13058-024-01776-y.
7
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.一种基于放射组学的方法来评估肿瘤浸润 CD8 细胞与抗 PD-1 或抗 PD-L1 免疫治疗反应的关系:一项影像学生物标志物、回顾性多队列研究。
Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.
8
Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.免疫检查点抑制剂治疗胃癌患者中炎症标志物 NLR、PLR 和 LMR 的预后价值:荟萃分析和系统评价。
Front Immunol. 2024 Jul 10;15:1408700. doi: 10.3389/fimmu.2024.1408700. eCollection 2024.
9
Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer.血清细胞因子和中性粒细胞与淋巴细胞比值可作为预测胃癌患者从 PD-1 抑制剂治疗中获益的生物标志物。
Front Immunol. 2023 Oct 31;14:1274431. doi: 10.3389/fimmu.2023.1274431. eCollection 2023.
10
Non-invasive measurement of tumor immune microenvironment and prediction of survival and chemotherapeutic benefits from F fluorodeoxyglucose PET/CT images in gastric cancer.基于 F 氟脱氧葡萄糖 PET/CT 图像无创测量胃癌肿瘤免疫微环境并预测生存和化疗获益。
Front Immunol. 2022 Oct 13;13:1019386. doi: 10.3389/fimmu.2022.1019386. eCollection 2022.

引用本文的文献

1
Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.利用外周血临床实验室组学数据的动态变化预测晚期胃癌免疫检查点抑制剂疗效的机器学习模型的开发与验证:一项回顾性多中心队列研究
Gastric Cancer. 2025 Sep 7. doi: 10.1007/s10120-025-01655-1.
2
Use of Radiomics in Characterizing Tumor Hypoxia.放射组学在肿瘤缺氧特征描述中的应用。
Int J Mol Sci. 2025 Jul 11;26(14):6679. doi: 10.3390/ijms26146679.
3
Gastrointestinal tumor personalized immunotherapy: an integrated analysis from molecular genetics to imaging biomarkers.

本文引用的文献

1
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.外周血中性粒细胞与淋巴细胞比值(dNLR)较低与非小细胞肺癌一线帕博利珠单抗治疗时肿瘤 T 细胞浸润增加和预后改善相关。
J Immunother Cancer. 2021 Nov;9(11). doi: 10.1136/jitc-2021-003536.
2
PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial.程序性死亡受体 1(PD-1)抗体卡瑞利珠单抗治疗爱泼斯坦-巴尔病毒阳性转移性胃癌:一项单臂、开放标签的 2 期试验。
Am J Cancer Res. 2021 Oct 15;11(10):5006-5015. eCollection 2021.
3
胃肠道肿瘤个性化免疫治疗:从分子遗传学到影像生物标志物的综合分析
Therap Adv Gastroenterol. 2025 Apr 23;18:17562848251333527. doi: 10.1177/17562848251333527. eCollection 2025.
4
Radiomics-based assessment of HER2 status and prognosis in gastric cancer: a retrospective dual-center CT study.基于影像组学的胃癌HER2状态及预后评估:一项回顾性双中心CT研究
Abdom Radiol (NY). 2025 Apr 8. doi: 10.1007/s00261-025-04912-0.
5
Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications.靶向B7-H3的肿瘤免疫疗法:从作用机制到临床应用
Immunotargets Ther. 2025 Mar 27;14:291-320. doi: 10.2147/ITT.S507522. eCollection 2025.
6
New approaches of chimeric antigen receptor (CAR)-immune cell-based therapy in gastric cancer; highlight CAR-T and CAR-NK.嵌合抗原受体(CAR)免疫细胞疗法在胃癌治疗中的新进展;重点介绍CAR-T和CAR-NK。
Funct Integr Genomics. 2025 Mar 25;25(1):72. doi: 10.1007/s10142-025-01584-3.
7
CT-based scores for extramural vascular invasion and occult peritoneal metastasis correlate with gastric cancer survival.基于CT的壁外血管侵犯和隐匿性腹膜转移评分与胃癌生存率相关。
Eur Radiol. 2025 Mar 18. doi: 10.1007/s00330-025-11491-7.
8
Expression, regulation, function and clinical significance of B7-H6 on neutrophils in human gastric cancer.B7-H6在人胃癌中性粒细胞上的表达、调控、功能及临床意义
Neoplasia. 2025 Apr;62:101149. doi: 10.1016/j.neo.2025.101149. Epub 2025 Mar 6.
9
Correlation of noninvasive imaging of tumour-infiltrating lymphocytes with survival and BCG immunotherapy response in patients with bladder cancer: a multicentre cohort study.膀胱癌患者肿瘤浸润淋巴细胞的非侵入性成像与生存及卡介苗免疫治疗反应的相关性:一项多中心队列研究
Int J Surg. 2025 Jan 1;111(1):920-931. doi: 10.1097/JS9.0000000000001999.
10
Tumor‑associated neutrophils: Critical regulators in cancer progression and therapeutic resistance (Review).肿瘤相关中性粒细胞:癌症进展和治疗耐药性的关键调节因子(综述)
Int J Oncol. 2025 Apr;66(4). doi: 10.3892/ijo.2025.5734. Epub 2025 Feb 28.
Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
抗 PD-1 抗体或联合抗 PD-1 加抗 CTLA-4 抗体,联合或不联合放疗,治疗晚期黏膜黑色素瘤患者的真实世界疗效:一项回顾性、多中心研究。
Eur J Cancer. 2021 Nov;157:361-372. doi: 10.1016/j.ejca.2021.08.034. Epub 2021 Sep 23.
4
PD-L1 is prognostic and a negative predictor of response to immunotherapy in gastric cancer.程序性死亡配体 1(PD-L1)在胃癌中是一种预后标志物和免疫治疗反应的阴性预测因子。
Mol Ther. 2022 Feb 2;30(2):621-631. doi: 10.1016/j.ymthe.2021.09.013. Epub 2021 Sep 20.
5
Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers.晚期胃食管腺癌的免疫检查点抑制剂耐药性。
Br J Cancer. 2021 Oct;125(8):1068-1079. doi: 10.1038/s41416-021-01425-7. Epub 2021 Jul 6.
6
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.利用 PET/CT 图像深度学习进行 PD-L1 状态的无创测量和免疫治疗反应预测。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002118.
7
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.中性粒细胞与淋巴细胞比值、肿瘤浸润淋巴细胞(CD4+/CD8+)及程序性死亡配体 1 表达对胃癌患者预后及术前化疗反应的预测价值。
Cancer Immunol Immunother. 2022 Jan;71(1):45-55. doi: 10.1007/s00262-021-02960-1. Epub 2021 May 19.
8
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials.微卫星不稳定性对晚期胃癌患者 PD-1 阻断的预测作用:随机临床试验的荟萃分析。
ESMO Open. 2021 Feb;6(1):100036. doi: 10.1016/j.esmoop.2020.100036. Epub 2021 Jan 15.
9
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.中性粒细胞与淋巴细胞比值(NLR)的变化可预测接受纳武利尤单抗治疗的转移性肾细胞癌(mRCC)和非小细胞肺癌(mNSCLC)患者的结局。
Cancer Immunol Immunother. 2020 Dec;69(12):2513-2522. doi: 10.1007/s00262-020-02637-1. Epub 2020 Jun 19.
10
Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer.纳武利尤单抗联合伊匹木单抗对比帕博利珠单抗作为无化疗一线治疗PD-L1阳性非小细胞肺癌的疗效
Clin Transl Med. 2020 Jan;10(1):107-115. doi: 10.1002/ctm2.14. Epub 2020 Apr 7.